Journal
CANCERS
Volume 12, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cancers12051322
Keywords
molecular imaging; tumor hypoxia; positron emission tomography (PET); [18F]-HX4; theranostics; response assessment
Categories
Funding
- ERC advanced grant (ERC-ADG-2015) [694812-Hypoximmuno]
- EUROSTARS [COMPACT-12053]
- European Program H2020-2015-17 [733008, 766276, 899549, 952172, 952103]
- TRANSCAN Joint Transnational Call 2016 (JTC2016 CLEARLY) [UM 2017-8295]
- Interreg V-A Euregio Meuse-Rhine (Euradiomics) [EMR4]
- Dutch Technology Foundation STW [10696, P14-19]
Ask authors/readers for more resources
Hypoxia-a common feature of the majority of solid tumors-is a negative prognostic factor, as it is associated with invasion, metastasis and therapy resistance. To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (PET). A plethora of hypoxia PET tracers, each with its own strengths and limitations, has been developed and successfully validated, thereby providing useful prognostic or predictive information. The current review focusses on [18F]-HX4, a promising next-generation hypoxia PET tracer. After a brief history of its development, we discuss and compare its characteristics with other hypoxia PET tracers and provide an update on its progression into the clinic. Lastly, we address the potential applications of assessing tumor hypoxia using [18F]-HX4, with a focus on improving patient-tailored therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available